Lingying Y. Wu

Chinese Academy Of Medical Science And Peking Union Medical College
Beijing, 100021, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.

Journal: Cancer biology & medicine
Published: June 02, 2026

Lactate-Induced ZMYM2 K529 Lactylation Stabilizes ZMYM2 and Promotes Platinum Resistance in Ovarian Cancer.

Lactate-Induced ZMYM2 K529 Lactylation Stabilizes ZMYM2 and Promotes Platinum Resistance in Ovarian Cancer.

Journal: International journal of molecular sciences
Published: April 12, 2026

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Journal: Chinese medical journal
Published: December 23, 2025

MMHC-OCPR: Prediction of Platinum Response and Recurrence Risk in Ovarian Cancer with Multimodal Deep Learning.

MMHC-OCPR: Prediction of Platinum Response and Recurrence Risk in Ovarian Cancer with Multimodal Deep Learning.

Journal: Biomedicines
Published: December 22, 2025

Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.

Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.

Journal: International journal of women's health
Published: October 31, 2025

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Tisotumab vedotin versus chemotherapy in Chinese patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.

Journal: Chinese medical journal
Published: September 22, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians
Published: September 15, 2025

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

Journal: Signal transduction and targeted therapy
Published: September 05, 2025

Safety and efficacy of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer after first-line PARPi maintenance therapy

Safety and efficacy of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer after first-line PARPi maintenance therapy

Journal: Zhonghua fu chan ke za zhi
Published: August 25, 2025

Landscape and challenges of PARPi in the treatment of epithelial ovarian carcinoma

Landscape and challenges of PARPi in the treatment of epithelial ovarian carcinoma

Journal: Zhonghua fu chan ke za zhi
Published: August 25, 2025

MRI evaluation of congenital vaginal malformations-a pictorial review.

MRI evaluation of congenital vaginal malformations-a pictorial review.

Journal: Clinical radiology
Published: July 23, 2025

Protocol for Quantifying γH2AX Foci in Irradiated Cells Using Immunofluorescence and Fiji Software.

Protocol for Quantifying γH2AX Foci in Irradiated Cells Using Immunofluorescence and Fiji Software.

Journal: Bio-protocol
Published: May 23, 2025
Showing 1-12 of 113

Last Updated: 09/26/2026